The Feasibility and Effects of Novel Light Therapy in Individuals with Neurological Conditions- Stroke

Edith Cowan University0 个研究点目标入组 58 人开始时间: 2021年7月15日最近更新: 2023年3月6日

适应症

试验速览

暂无简介。

•1)Have experienced an ischaemic or haemorrhagic stroke at least three months prior to enrolling in the study
•2)Have persistent self-reported fatigue: a score of greater than 4 on the Fatigue Severity Scale and/or a score of greater than or equal to 5 on the Pittsburgh Sleep Quality Index (indicative of self-perceived poor sleep quality) and/or a score of greater than or equal to 10 on the Epworth Sleepiness Scale (indicative of daytime somnolence)
•3)18 years of age or older
•4)Have a modified Rankin Score (mRS) of less than or equal to 4
•5)Have the capacity to speak reasonable English, understand verbal and written instructions and be able to complete tests and questionnaires without significant assistance
•6)Be able to give informed consent to participate in the study in accordance with the ICH GCP guidelines before initiating any study related procedures

•1)Untreated hallucinations or psychosis,
•2)Current use of hypnosedative or illicit stimulant drugs,
•3)Use of antidepressants, unless the participant has been receiving a stable dose for at least four weeks,
•4)Visual abnormalities that may interfere with light therapy, including cataracts, narrow-angle glaucoma or blindness,
•5)Transmeridian travel or night shift work in the six weeks leading up to the study (or the intention to travel or undertake night shift during the study),
•6)Severe untreated depression (defined by a score of greater than or equal to 11 on the depression component of the DASS-21)
•7)Pre-existing chronic fatigue syndrome, narcolepsy or sleep apnoea

发起方